UNITED THERAPEUTICS Corp financial data

Symbol
UTHR on Nasdaq
Industry
Pharmaceutical Preparations
Location
1000 Spring St, Silver Spring, MD
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 26, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 446 % -25.4%
Quick Ratio 17 % -9.68%
Debt-to-equity 17.5 % -22%
Return On Equity 20.3 % +14.4%
Return On Assets 17.3 % +19.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.9M shares +1.26%
Common Stock, Shares, Outstanding 44.8M shares -4.7%
Entity Public Float 12.2B USD +33%
Common Stock, Value, Issued 800K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 45.2M shares -3.42%
Weighted Average Number of Shares Outstanding, Diluted 48.5M shares -2.41%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.88B USD +23.6%
Research and Development Expense 481M USD +17.9%
Costs and Expenses 1.5B USD +31.3%
Operating Income (Loss) 1.38B USD +16.2%
Nonoperating Income (Expense) 162M USD +81.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.54B USD +20.8%
Income Tax Expense (Benefit) 344M USD +18.8%
Net Income (Loss) Attributable to Parent 1.2B USD +21.4%
Earnings Per Share, Basic 26.4 USD/shares +25.7%
Earnings Per Share, Diluted 24.6 USD/shares +24.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.7B USD +40.5%
Marketable Securities, Current 1.57B USD -12.1%
Accounts Receivable, after Allowance for Credit Loss, Current 279M USD +0.14%
Inventory, Net 158M USD +41.2%
Other Assets, Current 170M USD +2.11%
Assets, Current 3.87B USD +9.09%
Deferred Income Tax Assets, Net 458M USD +16.1%
Property, Plant and Equipment, Net 1.22B USD +16.9%
Goodwill 32.3M USD -4.15%
Other Assets, Noncurrent 222M USD +46.3%
Assets 7.36B USD +2.75%
Accounts Payable, Current 6M USD +7.14%
Employee-related Liabilities, Current 94.2M USD +29.2%
Accrued Liabilities, Current 339M USD +15.8%
Liabilities, Current 738M USD -8.24%
Other Liabilities, Noncurrent 182M USD +134%
Liabilities 920M USD -22.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.4M USD +73.4%
Retained Earnings (Accumulated Deficit) 7.22B USD +19.8%
Stockholders' Equity Attributable to Parent 6.44B USD +7.67%
Liabilities and Equity 7.36B USD +2.75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 377M USD +0.45%
Net Cash Provided by (Used in) Financing Activities -1.07B USD -2298%
Net Cash Provided by (Used in) Investing Activities 735M USD
Common Stock, Shares Authorized 245M shares 0%
Common Stock, Shares, Issued 75M shares +1.82%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 43.8M USD -78.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.7B USD +40.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 12.6M USD -3.82%
Deferred Tax Assets, Valuation Allowance 30.1M USD -2.27%
Deferred Tax Assets, Gross 563M USD +18.8%
Payments to Acquire Property, Plant, and Equipment 38.2M USD -7.51%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.2B USD +17.2%
Lessee, Operating Lease, Liability, to be Paid 38.6M USD +17.7%
Property, Plant and Equipment, Gross 1.71B USD +16.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6M USD +39.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.1M USD +29.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.1M USD +45.2%
Deferred Tax Assets, Operating Loss Carryforwards 19.8M USD -7.48%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 19.6M USD -18.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.8M USD +38.1%
Depreciation, Depletion and Amortization 15M USD +12.8%
Deferred Tax Assets, Net of Valuation Allowance 533M USD +20.2%
Share-based Payment Arrangement, Expense 144M USD +268%
Interest Expense 58.8M USD +41.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%